节点文献

新辅助治疗后SUVmax是可手术非小细胞肺癌的预后标志物

SUVmax After Neoadjuvant Therapy as a Prognostic Marker for Operable Non-Small Cell Lung Cancer

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 林俊涛孙铭叶凯雁国灏刘思旸侯庆仪廖日强聂强董嵩江本元钟文昭吴一龙杨学宁

【Author】 LIN Jun-tao;SUN Ming;YE Kai-yan;GUO Hao;LIU Si-yang;HOU Qing-yi;LIAO Ri-qiang;NIE Qiang;DONG Song;JIANG Ben-yuan;ZHONG Wen-zhao;WU Yi-long;YANG Xue-ning;Guangdong Lung Cancer Institute,Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer,Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences),Southern Medical University;State Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Ren Ji Hospital,Shanghai Jiao Tong University School of Medicine;Department of PET Center,Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences),Southern Medical University;

【通讯作者】 吴一龙;杨学宁;

【机构】 南方医科大学附属广东省人民医院(广东省医学科学院),广东省肺癌转化医学重点实验室,广东省肺癌研究所上海交通大学医学院附属仁济医院,上海市肿瘤研究所,肿瘤系统医学全国重点实验室南方医科大学附属广东省人民医院(广东省医学科学院),PET-CT中心

【摘要】 背景 最大标准化摄取值(maximum standardized uptake value,SUVmax)是不可手术Ⅲ~Ⅳ期非小细胞肺癌(non-small cell lung cancer,NSCLC)的预后因素。然而,SUVmax对接受了新辅助治疗的早期NSCLC的预后作用仍存在争议。本研究分析了这些患者的SUVmax与生存率之间的相关性。患者和方法 回顾性分析2008年1月至2017年12月广东省人民医院64例新辅助治疗后进行根治性手术的ⅠA~ⅢB期NSCLC。患者在新辅助治疗前后均进行正电子发射断层扫描/计算机断层扫描(Positron emission tomography/computed tomography,PET/CT)。使用Kaplan-Meier和log-rank法计算和比较无病生存期(disease-free survival,DFS)和总生存期(overall survival,OS)。通过COX比例风险模型确定预后因素,而代谢因素的预测效能通过受试者操作特征曲线(receiver operating characteristics curve,ROC)与ROC曲线下面积(area under the ROC curve,AUC)进行对比。结果 SUVmax2(新辅助治疗后的SUVmax)是DFS(P=0.019,AUC=0.702)和OS(P<0.001,AUC=0.746)的独立预后因素。在手术后42个月的ROC分析中,DFS(敏感性:0.566,特异性:0.818)和OS(敏感性:0.800,特异性:0.636)的SUVmax2的临界值为6。以SUVmax2临界值将患者分为两组:SUVmax2≥6,SUVmax2<6,并进行生存分析,提示SUVmax2对DFS(13.1个月vs.21.9个月;P=0.023)和OS(23.1个月vs. 56.4个月;P<0.001)具有预后作用。结论 SUVmax2是新辅助治疗后NSCLC患者DFS和OS的潜在独立预后因素,可作为新辅助疗法后区分高危和低危患者的参数。

【Abstract】 Background The maximum standardized uptake value(SUVmax) is a prognostic factor of inoperable advanced(stage Ⅲ and Ⅳ) non-small cell lung cancer(NSCLC). However, the role of SUVmax in early-stage NSCLC patients who underwent neoadjuvant therapy is debated. In this study, we examined the correlation between SUVmax and survival among these patients. Patients and methods Sixty-four patients with stage ⅠA~ⅢB NSCLC who underwent neoadjuvant therapy followed by curative-intent surgery in Guangdong Provincial People’s Hospital were retrospectively reviewed from January 2008 to December 2017. Positron emission tomography/computed tomography(PET/CT) was performed before and after neoadjuvant therapy. Prognostic factors were determined by the COX proportional hazard model, while metabolic factors were compared by receiver operating characteristics curve(ROC) with area under the ROC curve(AUC) values. Disease-free survival(DFS) and overall survival(OS) were estimated and compared by KaplanMeier and log-rank analyses, respectively. Results SUVmax2(SUVmax after neoadjuvant therapy) was found to be an independent prognostic factor of DFS(P=0.019, AUC=0.702) and OS(P<0.001, AUC=0.746). The cutoff value of SUVmax2 was 6.0 in the ROC analysis at 42 months after surgery for DFS(sensitivity: 0.566, specificity: 0.818) and OS(sensitivity: 0.800, specificity: 0.636). The survival curves dichotomized at the SUVmax2 cutoff value were significantly correlated with DFS(SUVmax2≥6, SUVmax2<6, median: 13.1 months vs. 21.9 months; P=0.023) and OS(SUVmax2≥6,SUVmax2<6, median: 23.1 months vs. 56.4 months; P<0.001). Conclusion As a potential independent prognostic factor for DFS and OS in patients with NSCLC after neoadjuvant therapy, SUVmax2 may serve as a stratification parameter after neoadjuvant treatment for assessment of high and low-risk patients.

【基金】 广东省医学科学技术研究基金(A2024743);广东省人民医院国家自然科学基金启动基金(KY012021920);广东省科技厅重点实验室建设项目(2017B030314120);国家自然科学基金肺癌关键科学问题重大联合专项(82241235);国家卫健委医药卫生科技发展研究中心(WKZX2023YG0401);第七批国家高层次人才特殊支持计划入选人才2022年特殊支持经费(KA0120231004)
  • 【文献出处】 循证医学 ,The Journal of Evidence-Based Medicine , 编辑部邮箱 ,2025年01期
  • 【分类号】R734.2
  • 【下载频次】28
节点文献中: 

本文链接的文献网络图示:

本文的引文网络